- Home
- TRIP vs GLPG Comparison
TRIP vs GLPG Comparison
Compare TRIP & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- GLPG
- Stock Information
- Founded
- TRIP 2000
- GLPG 1999
- Country
- TRIP United States
- GLPG Belgium
- Employees
- TRIP N/A
- GLPG N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- TRIP Technology
- GLPG Health Care
- Exchange
- TRIP Nasdaq
- GLPG Nasdaq
- Market Cap
- TRIP 2.0B
- GLPG 2.1B
- IPO Year
- TRIP 2011
- GLPG 2005
- Fundamental
- Price
- TRIP $17.73
- GLPG $32.02
- Analyst Decision
- TRIP Hold
- GLPG Sell
- Analyst Count
- TRIP 9
- GLPG 4
- Target Price
- TRIP $17.25
- GLPG $25.33
- AVG Volume (30 Days)
- TRIP 2.0M
- GLPG 230.8K
- Earning Date
- TRIP 11-05-2025
- GLPG 10-29-2025
- Dividend Yield
- TRIP N/A
- GLPG N/A
- EPS Growth
- TRIP 165.58
- GLPG N/A
- EPS
- TRIP 0.46
- GLPG N/A
- Revenue
- TRIP $1,870,000,000.00
- GLPG $323,674,692.00
- Revenue This Year
- TRIP $7.36
- GLPG N/A
- Revenue Next Year
- TRIP $7.66
- GLPG N/A
- P/E Ratio
- TRIP $38.50
- GLPG N/A
- Revenue Growth
- TRIP 3.03
- GLPG 5.43
- 52 Week Low
- TRIP $10.43
- GLPG $22.36
- 52 Week High
- TRIP $19.26
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- TRIP 54.19
- GLPG 49.28
- Support Level
- TRIP $17.20
- GLPG $30.88
- Resistance Level
- TRIP $18.20
- GLPG $33.63
- Average True Range (ATR)
- TRIP 0.56
- GLPG 0.69
- MACD
- TRIP 0.04
- GLPG -0.02
- Stochastic Oscillator
- TRIP 68.42
- GLPG 41.45
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.